Key result
In patients with device-detected subclinical atrial fibrillation and a history of stroke or TIA, apixaban significantly reduced the risk of stroke or systemic embolism with an absolute risk difference of 7% compared to aspirin.
Why the study?
Does apixaban reduce stroke or systemic embolism in patients with subclinical atrial fibrillation and a history of stroke or transient ischemic attack?
Does apixaban reduce stroke or systemic embolism in patients with subclinical atrial fibrillation and a history of stroke or transient ischemic attack?
Answers are grounded in this paper and cite their sources.
In patients with device-detected subclinical atrial fibrillation and a prior stroke or TIA, apixaban is indicated for secondary stroke prevention due to a significant reduction in stroke or systemic embolism.
I read with interest the subgroup analysis of the ARTESiA trial recently published in Lancet Neurology....
No takes yet. Share an insight, caveat, or question.
Vittorio Pengo (2025) conducted an editorial in Subclinical device-detected atrial fibrillation and a history of stroke or transient ischemic attack (n=346). Apixaban vs. Aspirin 81 mg daily was evaluated on Stroke or systemic embolism (ARR 7%). In patients with device-detected subclinical atrial fibrillation and a history of stroke or TIA, apixaban significantly reduced the risk of stroke or systemic embolism with an absolute risk difference of 7% compared to aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: